Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsHarpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
Estimating the term…
The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.
A peptide comprising a sequence of SEQ ID No. 2 and/or a variant thereof which is capable of inducing T cells cross-reacting with said peptide and/or a variant, and wherein said peptide and/or variant has an overall length from 8 to 100 amino acids.
Dependencies are inferred from the claim text.